The dose of febuxostat required to achieve the target level of uric acid in patients with normal and impaired renal function
Febuxostat (FS) is the drug of choice in impaired renal function, but the dosage regimen and the actual efficacy of the maximum allowable doses required to achieve the target uric acid (UA) level in patients with impaired renal function have not been adequately studied.Objective: to compare the dosa...
Saved in:
| Main Authors: | M. S. Eliseev, M. N. Chikina, O. V. Zhelyabina, Ya. I. Kuzmina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2025-04-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1745 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Febuxostat in the therapy of gout: from theory to practice
by: E. V. Ilyinykh, et al.
Published: (2018-01-01) -
Febuxostat in patients with hyperuricemia and gout: is the nephroprotective effect real?
by: M. S. Eliseev, et al.
Published: (2024-10-01) -
UPDATED EULAR GUIDELINES FOR THE MANAGEMENT OF GOUT. COMMENTS ON CERTAIN ITEMS
by: M. S. Eliseev
Published: (2018-01-01) -
Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)
by: M. S. Eliseev
Published: (2020-09-01) -
Type 2 diabetes mellitus and gout
by: O. V. Zhelyabina, et al.
Published: (2021-10-01)